Larimar Therapeutics, Inc.

General ticker "LRMR" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $390.5M (TTM average)

Larimar Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -2.5%.

Estimated limits based on current volatility of 6.5%: low 2.58$, high 2.93$

Factors to consider:

  • Earnings expected soon, date: 2025-05-08 bmo
  • Company does not operate outside North America (retrieved using AI)
  • Price in estimated range

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-12-31 to 2026-12-31

  • 2024-12-31 to 2025-12-31 estimated range: [1.64$, 4.61$]
  • 2025-12-31 to 2026-12-31 estimated range: [1.07$, 3.07$]

Financial Metrics affecting the LRMR estimates:

  • Negative: Non-GAAP EPS, $ of -1.30 <= 0.04
  • Negative: Operating cash flow per share per price, % of -17.40 <= 1.79
  • Negative: negative Net income
  • Negative: negative Operating income
  • Negative: Shareholder equity ratio, % of 85.81 > 63.75
  • Positive: Inventory ratio change, % of 0 <= 0
  • Negative: Industry operating cash flow per share per price (median), % of -21.10 <= 2.82
  • Positive: Industry inventory ratio change (median), % of 0 <= 0
  • Positive: Interest expense per share, $ of 0 <= 0

Similar symbols

Short-term LRMR quotes

2025-03-212025-03-242025-03-252025-03-262025-03-272025-03-282025-03-312025-04-012025-04-022025-04-032025-04-042025-04-072025-04-082025-04-092025-04-102025-04-112025-04-142025-04-152025-04-162025-04-172025-04-212025-04-222025-04-232025-04-242025-04-252025-04-282025-04-292025-04-302025-05-012025-05-021.61.822.22.42.62.83
Price $

Long-term LRMR plot with estimates

2468101214Jul 2023Jan 2024Jul 2024Jan 2025Jul 2025Jan 2026Jul 2026Jan 2027−0.4−0.3−0.2−0.10
LRMRS&P500Health CareNon-GAAP EPS EstimateNon-GAAP EPS ActualPrice $Non-GAAP EPS $

Financial data

YTD 2022-12-31 2023-12-31 2024-12-31
Operating Revenue $0.00MM $0.00MM $0.00MM
Operating Expenses $36.53MM $41.76MM $90.89MM
Operating Income $-36.53MM $-41.76MM $-90.89MM
Non-Operating Income $1.17MM $4.81MM $10.29MM
R&D Expense $24.25MM $27.67MM $73.28MM
Income(Loss) $-35.35MM $-36.95MM $-80.60MM
Profit(Loss)* $-34.18MM $-36.95MM $-80.60MM
Stockholders Equity $110.90MM $81.72MM $171.81MM
Assets $126.41MM $95.94MM $200.22MM
Operating Cash Flow $-27.57MM $-33.46MM $-70.76MM
Capital expenditure $0.10MM $0.16MM $0.52MM
Investing Cash Flow $-90.96MM $33.35MM $-85.39MM
Financing Cash Flow $75.26MM $0.03MM $161.88MM
Earnings Per Share** $-1.33 $-0.84 $-1.32

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.